|| Checking for direct PDF access through Ovid
Dexmedetomidine, the highly selective α2-adrenergic agonist, produces a dose-dependent hypnotic response in rats through a central mechanism. Because the locus coeruleus (LC) contains pathways involved in the maintenance of vigilance and a high prevalence of α2-adrenoceptors, we investigated the role of this brainstem nucleus in the hypnotic response to dexmedetomidine. The experimental model consisted of chronic, stereotactially cannulated rats (n = 157) in which the hypnotic response to dexmedetomidine was assessed by the duration of the loss of their righting reflex. Correct placement of the cannula was confirmed histologically at necropsy. The hypnotic response to dexmedetomidine 0.3 – 333.3 μg administered into the LC increased in a dose-dependent fashion. Dexmedetomidine 6.6 μg injected 2 mm lateral to the LC did not cause the animals to lose their righting response. Atipamezole 0.07 μg – 12 μg, a selective α2-adrenergic antagonist, blocked the hypnotic response to dexmedetomidine 6.6 μg when both were administered into the LC. Also, atipamezole 0.7 – 30 μg, administered into the LC, blocked in a dose-dependent manner the hypnotic response to intraperitoneal (ip) dexmedetomidine 50 μg.kg–1. Alipamezole injected into the LC did not block the hypnotic response to pentobarbital 40 mg.kg–1 ip. Prazosin, an α2-adrenergic antagonist, 4.2 μg into the LC or 1.0 mg.kg–1 ip, did not alter the hypnotic response to dexmedetomidine 6.6 μg into the LC. The present data suggest that α2-adrenergic receptors in the LC appear to be a major site for the hypnotic action of dexmedetomidine. This discrete region can now be probed with specific toxins in order to define the postreceptor molecular components involved in the transduction mechanism for the hypnotic response to α2-adrenergic agonists.